Autolus to cut about 13% of workforce in cost reduction...

2026-04-29 16:20:20 ET More on Autolus Therapeutics Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights - Slideshow Autolus Therapeutics: Q4 Earnings Highlight Importance Of Autoimmune Data Catalysts Asgard Therapeutics names Wolfram Brugger as chief medical officer to lead clinical transition Autolus reiterates $120M-$135M AUCATZYL revenue target for 2026 while expanding pivotal trial pipeline Read the full article on Seeking Alpha For further details see: Autolus to cut about 13% of workforce in cost reduction initiative